Howard C Chen

US Patent:

6377645, Apr 23, 2002

Filed:

May 7, 1999

Appl. No.:

09/307012

Inventors:

Howard Zehua Chen - Berkeley Heights NJ
Keith James Monteleone - Whitehouse Station NJ
Edward Stanley Szurkowski - Maplewood NJ

Assignee:

Lucent Technologies Inc. - Murray Hill NJ

International Classification:

G06F 1300

US Classification:

375372, 375356, 370235, 370468

Abstract:

A method and apparatus for controlling bit slips in a high-speed, two-way, communications channel. More particularly, the entire communications system, comprising, inter alia, a receiver, a transmitter and the physical communications channel is operated as a feedback loop. That is, the detection of bit slips is performed continuously in the receiver and a bit slip signal is generated that indicates the number of bit slips and the direction, i. e. , forward or backward, of the bit slip. Thus, the bit slip signal is communicated to the transmitter and certain actions are performed to introduce bit adjustments in the bit stream to eliminate the effects of any future bit slips. The bit slip signal contains an indication of the number of bit slips which have occurred, the time between bit slips, and the direction of the slip. As a function of this information from the bit slip signal, bit adjustments are made in the communications stream to correct for the bit slips and mitigate any effect in future transmission. For example, such bit adjustments include adding bits to particular data words in the bit stream or repositioning pointers used to traverse the data stream.

US Patent:

6639123, Oct 28, 2003

Filed:

Nov 9, 2000

Appl. No.:

09/709066

Inventors:

Leonardus H. T. Van der Ploeg - Sctoch Plains NJ
Howard Y. Chen - Westfield NJ
Airu S. Chen - Westfield NJ

Assignee:

Merck Co., Inc. - Rahway NJ

International Classification:

A01K 67027

US Classification:

800 18, 800 13, 800 14, 800 21, 800 25, 435325, 435352, 435354, 435361

Abstract:

Cells and non-human transgenic animals have been engineered to be deficient in the gene encoding the melcanocortin-3 receptor protein (MC-3R). MC-3R deficient transgenic animals have increased fatmass and reduced lean body mass, showing that the MC-3R protein is involved in the regulation of body fat and muscle mass. These MC-3R deficient transgenic animals can be used to select for and test potential modulators of MC-3R. This data allows for methods of screening for MC-3R modulators which effect body weight and associated methods of treating various disorders associated with inappropriate regulation of body weight. The disclosure also relates to a MC-3R/MC-4R double knockout mouse which can be used to select for and test potential modulators (e. g. , agonists or antagonists) of MC-3R and/or MC-4R. It is shown that MC-3R serves a non-redundant role, when compared to MC-4R, in the regulation of energy homeostasis.

US Patent:

7321074, Jan 22, 2008

Filed:

Nov 9, 2000

Appl. No.:

10/129599

Inventors:

Leonardus H. T. Van Der Ploeg - Scotch Plains NJ, US
Howard Y. Chen - Westfield NJ, US
Airu S. Chen - Westfield NJ, US

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A01K 67/027
C12N 5/00
C12N 5/06
C12N 5/10

US Classification:

800 18, 435325, 435352, 435354

Abstract:

Cells and non-human transgenic animals have been engineered to be deficient in the gene encoding the melcanocortin-3 receptor protein (MC-3R). MC-3R deficient transgenic animals have increased fatmass and reduced lean body mass, showing that the MC-3R protein is involved in the regulation of body fat and muscle mass. These MC-3R deficient transgenic animals can be used to select for and test potential modulators of MC-3R. This data allows for methods of screening for MC-3R modulators which effect body weight and associated methods of treating various disorders associated with inappropriate regulation of body weight. The disclosure also relates to a MC-3R/MC-4R double knockout mouse which can be used to select for and test potential modulators (e. g. , agonists or antagonists) of MC-3R and/or MC-4R. It is shown that MC-3R serves a non-redundant role, when compared to MC-4R, in the regulation of energy homeostasis.

US Patent:

20040122033, Jun 24, 2004

Filed:

Dec 8, 2003

Appl. No.:

10/730704

Inventors:

Ravi Nargund - East Brunswick NJ, US
Leonardus Van Der Ploeg - Scotch Plains NJ, US
Tung Fong - Somerset NJ, US
Douglas MacNeil - Westfield NJ, US
Howard Chen - Westfield NJ, US
Donald Marsh - Hillsborough NJ, US
Jeffrey Warmke - Edison NJ, US

International Classification:

A61K031/485
A61K031/19

US Classification:

514/282000, 514/571000

Abstract:

The present invention relates to compositions comprising an appetite suppressant and/or a metabolic rate enhancer and/or a nutrient absorption inhibitor useful for the treatment of obesity, and obesity-related disorders. The present invention further relates to methods of treating or preventing obesity, and obesity-related disorders, in a subject in need thereof by administering a composition of the present invention. The present invention further provides for pharmaceutical compositions, medicaments, and kits useful in carrying out these methods.

US Patent:

20050034185, Feb 10, 2005

Filed:

Jun 25, 2003

Appl. No.:

10/603249

Inventors:

Leonardus Van der Ploeg - Sctoch Plains NJ, US
Howard Chen - Westfield NJ, US
Airu Chen - Westfield NJ, US

Assignee:

Merek & Co., Inc. - Rahway NJ

International Classification:

A01K067/027
C12N005/06

US Classification:

800018000, 435354000

Abstract:

Cells and non-human transgenic animals have been engineered to be deficient in the gene encoding the melcanocortin-3 receptor protein (MC-3R). MC-3R deficient transgenic animals have increased fatmass and reduced lean body mass, showing that the MC-3R protein is involved in the regulation of body fat and muscle mass. These MC-3R deficient transgenic animals can be used to select for and test potential modulators of MC-3R. This data allows for methods of screening for MC-3R modulators which effect body weight and associated methods of treating various disorders associated with inappropriate regulation of body weight. The disclosure also relates to a MC-3R/MC-4R double knockout mouse which can be used to select for and test potential modulators (e.g., agonists or antagonists) of MC-3R and/or MC-4R. It is shown that MC-3R serves a non-redundant role, when compared to MC-4R, in the regulation of energy homeostasis.

US Patent:

20050257279, Nov 17, 2005

Filed:

Jun 27, 2003

Appl. No.:

10/518955

Inventors:

Su Qian - Princeton NJ, US
Leonardus Van der Ploeg - Scotch Plains NJ, US
Howard Chen - Westfield NJ, US
Drew Weingarth - East Brunswick NJ, US
Myrna Trumbauer - Yardley PA, US
Joseph Metzger - Fanwood NJ, US

International Classification:

A01K067/027
C12N005/06

US Classification:

800018000, 435354000

Abstract:

Cells and non-human transgenic animals have been engineered to be deficient in the gene encoding agouti-related protein (AgRP). AgRP deficient transgenic animals have a reduced day time respiratory quotient (RQ), indicating that AgRP is involved in the regulation of energy metabolism, resulting in the reduced usage of fat as an energy source. These AgRP deficient transgenic animals can be used to select for and test potential modulators of AgRP. This data allows for methods of screening for AgRP modulators which regulate energy metabolism and caloric utilization. The disclosure also relates to a NPY/AgRP double knockout mouse which can be used to select for and test potential modulators (e.g., agonists or antagonists) of AgRP and/or NPY.

US Patent:

20080172752, Jul 17, 2008

Filed:

Jan 17, 2007

Appl. No.:

11/654155

Inventors:

Howard Y. Chen - Westfield NJ, US
Danald J. Marsh - Hillsborough NJ, US

International Classification:

C12N 15/00
A01K 67/027
C12N 5/06

US Classification:

800 24, 435354, 800 18

Abstract:

Transgenic mice that have been engineered to be deficient in the gene encoding the neuromedin receptor subtype 1 gene. Such mice are useful in screening for receptor subtype-specific agonists and antagonists.

US Patent:

58248374, Oct 20, 1998

Filed:

Apr 22, 1996

Appl. No.:

8/571983

Inventors:

Howard Y. Chen - Westfield NJ
Kathryn J. Hofmann - Collegeville PA
Leonardus H. T. Van Der Ploeg - Scotch Plains NJ
Alan R. Shaw - Doylestown PA
Myrna E. Trumbauer - Yardley PA
Hui Zheng - Edison NJ

Assignee:

Merck & Co., Inc. - Rahway NJ

International Classification:

A61K 4900
C12N 518
C12N 1509
C12N 1516

US Classification:

800 2

Abstract:

A transgenic mouse has been prepared that expresses a human interluekin-1. beta. transgene. Expression of the transgene is mediated by a mouse metallothionein promoter. As a result of the expression of this transgene, the mouse has inflammation of its kidney and liver. The claimed animals are useful as screening tools for agents that are potentially useful for treating inflammation.